Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2001

01-06-2001

Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples

Authors: Gottfried Konecny, Michael Untch, Dennis Slamon, Malgorzata Beryt, Steffen Kahlert, Margret Felber, Elena Langer, Sandra Lude, Hermann Hepp, Mark Pegram

Published in: Breast Cancer Research and Treatment | Issue 3/2001

Login to get access
Metadata
Title
Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples
Authors
Gottfried Konecny
Michael Untch
Dennis Slamon
Malgorzata Beryt
Steffen Kahlert
Margret Felber
Elena Langer
Sandra Lude
Hermann Hepp
Mark Pegram
Publication date
01-06-2001
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 3/2001
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1017980411398

Other articles of this Issue 3/2001

Breast Cancer Research and Treatment 3/2001 Go to the issue

OriginalPaper

Loss of androgen receptor associated protein 70 (ARA70) expression in a subset of HER2-positive breast cancers

OriginalPaper

Mental adjustment to first recurrence and correlated factors in patients with breast cancer

OriginalPaper

Omega-3 fatty acids decrease protein kinase expression in human breast cancer cells

OriginalPaper

Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways

OriginalPaper

MUC1 expression in primary breast cancer: the effect of tamoxifen treatment

Subject Index

Subject Index, Volume 67
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits